| abstract |
REFER TO COMPOUNDS OF FORMULA (I), WHERE: "X" IS -O-, -NH-, -CH2-, -S-, -SO2-, -CH =, -CO2-, -CONH-, - WITH (LOWER RENT); R1, R2, R3 and R4 ARE H, HALOGEN, HYDROXYL, AMINO, NITRO, LOWER ALKYL-SULFONYLAMIDE, PREFERRED METHANOSULFONYLAMIDE, 1- or 2- IMIDAZOLYL, 1- (1,2,4-TRIAZOLYL); R5 AND R6 ARE H, LOWER ALKYL, HYDROXYL, LOWER ALCOXYL OR OXO; R7, R8, R9 AND R10 ARE H, LOWER ALKYL, METHYL PREFERENCE, HALOGEN, PREFERENCE F or Cl, CF3 OR LOWER ALKOXYL; n IS 0 or 1. ALSO REFERS TO THE PROCEDURES FOR PREPARING COMPOUNDS (I); THE SAME AS ACTING AS SELECTIVE BLOCKERS OF THE N-METHYL-D-ASPARTATE (NMDA) RECEPTOR SUBTYPES, PREFERENTIALLY NMDAR-2B SUBUNITES, WHICH MODULATE THE NEURONAL ACTIVITY AND PLASTICITY, BEING USEFUL IN THE NEURONAL TREATMENT TREATMENT LIKE ALZHEIMER, PARKINSON, HUNTINGTON DISEASE, AMYOTROPHIC LATERAL SCLEROSIS, NEURODEGENERATION ASSOCIATED WITH BACTERIAL OR VIRIC INFECTIONS, AMONG OTHERS |